One-year clinical experience on the use of Nintedanib in systemic sclerosis.
autoimmunity
fibrosis
interstitial lung disease
rare disease
systemic sclerosis
Journal
Respirology case reports
ISSN: 2051-3380
Titre abrégé: Respirol Case Rep
Pays: United States
ID NLM: 101631052
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
13
09
2022
accepted:
24
02
2023
medline:
25
5
2023
pubmed:
25
5
2023
entrez:
25
5
2023
Statut:
epublish
Résumé
We reviewed 11 patients with systemic sclerosis-related ILD who were referred to our Scleroderma Unit from January 2020 to January 2021 and started Nintedanib. Non-specific interstitial pneumonia (NSIP) was prevalent (45%), usual interstitial pneumonia (UIP) and UIP/NSIP pattern were both 27%. Only one patient had a history of smoking. Eight patients were on mycophenolate mofetil (MMF), eight were treated with corticosteroids (mean dose 5 mg/day of Prednisone or equivalent), and three were on Rituximab. The mean modified British Council Medical Questionnaire (mmRC) decreased from 3 to 2.5. Two patients had to reduce their daily dose to 200 mg/day for severe diarrhoea. Nintedanib was generally well tolerated.
Identifiants
pubmed: 37229296
doi: 10.1002/rcr2.1120
pii: RCR21120
pmc: PMC10203787
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e01120Informations de copyright
© 2023 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology.
Déclaration de conflit d'intérêts
None declared.
Références
J Rheumatol. 1988 Feb;15(2):202-5
pubmed: 3361530
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
N Engl J Med. 2019 Jun 27;380(26):2518-2528
pubmed: 31112379
Arch Dermatol. 1961 Sep;84:359-71
pubmed: 13778561
N Engl J Med. 2019 Oct 31;381(18):1718-1727
pubmed: 31566307